Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteasome activator complex subunit 2 (PSME2) encodes the beta subunit of the 11S regulator (PA28) complex, a proteasome activator that forms a heterohexameric ring with alpha and beta subunits. This regulator can replace the 19S cap on the 20S proteasome, especially in interferon-gamma induced immunoproteasomes, thereby enhancing the generation of class I MHC binding peptides for antigen presentation. The PA28 complex modulates the proteolytic activity of the core proteasome, affecting immune response, protein turnover, and cellular homeostasis. PSME2's function is critical for efficient antigen processing, and altered expression has been associated with disease states such as cancer, immunodeficiency, and inflammatory conditions[1][2][6][7].
No approved therapies directly targeting PSME2; immunoproteasome modulation—by analogy with other proteasome components—involves altering antigen presentation and immune response
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome activator complex subunit 2 (PSME2).